Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0650

0.0%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Howard Williams	6/28/2013 12:40:05 PM
	5 Recommendations Recommended By Khris Smith Littlebits pincus Rutgers travisnye Read Replies (1) of 13111

Annual Meeting snippets Based on a phone call from an attendee who traveled to Knoxville for the event, these items are not in chronological order and hopefully have few errors resulting from my scribbled notes. The official annual meeting was dispatched quickly and efficiently. This was followed by Dr. Dees holding forth for almost three hours, wide ranging discussion/presentation. Thrifty setup: Refreshments were popcorn, mints and soda pop. No Jolly Rancher candies (inside joke). About ten shareholders in attendance. FDA "in transition" .... somewhat disorganized, Congressional mandates take time to assimilate. Younger newcomers not as enthused about BTD as older/seasoned troops. PVCT working all angles to get PV-10 approved. No timetable projected. Working to get a simple, narrow approval. That'll open PV-10 up for off label use. PV-10 is easy and cheap to produce in very precise compositions. Outstanding shelf life. Lots of interest in China for liver cancer due to high numbers of new and ongoing cases. Ten Chinese drug companies came to the PVCT meetings in China. Japan, China and India all in play. PVCT in a much better position than a year ago. If licensing dollars arrive, a high priority use will be share buybacks ....... They feel PVCT is grossly undervalued. Dees is very high on PH-10 for derm also. Compassionate Use Program .............. This is reportedly going very well. Excellent patient responses to PV-10. This is not a structured/reporting study or trial. PVCT makes PV-10 available at no cost to carefully selected doctors. Outcomes are not reported to the FDA .... UNLESS there is a negative outcome or effect attributable to PV-10. Apparently there have been no such reports. It sounds like reports come to PVCT only anecdotally. IMO it would be nice (understatement) to somehow collect information and compile the CUP outcome information. Clearly, HIPPA rules have to be adhered to. One doctor in Louisville is a superstar when it comes to the CUP according to Dees. The Moffitt data have been instrumental in attracting big pharma interests. Due to PV-10's virtually nonexistent detrimental side effects, PVCT believes it can play an important role in treating cancer in pregnant women. Fetuses should be completely unharmed. That's not the case with many chemotherapies. Veterinary uses have potential as well. Work has been done with horses, dogs and cats. In humans, the most important PV-10 uses will be in cancers that cannot be treated effectively by surgical removal. Breast and prostate cancer have effective surgical treatments. There are indications (lab murine studies?) that PV-10 is effective on Bladder cancer. That's all for now. If any other posters attended, I'm sure we'd all welcome their comments/corrections.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next